Search company, investor...

PhaseBio Pharmaceuticals

Founded Year




Total Raised


Date of IPO


Market Cap


About PhaseBio Pharmaceuticals

PhaseBio Pharmaceuticals (PHAS) is a clinical-stage biopharmaceutical company developing drugs to treat diabetes and cardiovascular dysfunction in patients suffering from rare diseases. The Company's discovery platform technology uses recombinant ELP biopolymers to control the half-life, bioavailability and physical characteristics of molecules for ease of administration. The resulting compounds are tuned for a specific rate of absorption, thereby increasing efficacy and reducing side effects.

Headquarters Location

1 Great Valley Parkway Suite 30

Malvern, Pennsylvania, 19355,

United States


Missing: PhaseBio Pharmaceuticals's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: PhaseBio Pharmaceuticals's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing PhaseBio Pharmaceuticals

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

PhaseBio Pharmaceuticals is included in 2 Expert Collections, including Diabetes.



1,903 items


Biopharma Tech

838 items

PhaseBio Pharmaceuticals Patents

PhaseBio Pharmaceuticals has filed 28 patents.

The 3 most popular patent topics include:

  • Transcription factors
  • Cardiac arrhythmia
  • Rare diseases
patents chart

Application Date

Grant Date


Related Topics




Cardiac arrhythmia, Transcription factors, Rare diseases, Clusters of differentiation, Muscular dystrophy


Application Date


Grant Date



Related Topics

Cardiac arrhythmia, Transcription factors, Rare diseases, Clusters of differentiation, Muscular dystrophy



Latest PhaseBio Pharmaceuticals News

SFJ Pharma closes transfer of bentracimab assets from PhaseBio

Jan 18, 2023

SFJ Pharmaceuticals is claiming victory in its legal dispute with cardiopulmonary diseases focussed US firm PhaseBio Pharmaceuticals (Nasdaq: PHAS) regarding a blood thinner reversal agent, announcing the closing of the sale and transfer of assets related to bentracimab from PhaseBio to SFJ, a California-based drug development company backed by Blackstone Life Sciences and Abingworth. The sale and transfer was approved on December 31, 2022, by the… This article is accessible to registered users, to continue reading please register for free . A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please  login . If your trial has come to an end, you can  subscribe here. • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech. • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results. • Daily roundup of key events in pharma and biotech. • Monthly in-depth briefings on Boardroom appointments and M&A news. • Choose from a cost-effective annual package or a flexible monthly subscription. If you are already a registered user please login . The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed Chairman, Sanofi Aventis UK

PhaseBio Pharmaceuticals Frequently Asked Questions (FAQ)

  • When was PhaseBio Pharmaceuticals founded?

    PhaseBio Pharmaceuticals was founded in 2002.

  • Where is PhaseBio Pharmaceuticals's headquarters?

    PhaseBio Pharmaceuticals's headquarters is located at 1 Great Valley Parkway, Malvern.

  • What is PhaseBio Pharmaceuticals's latest funding round?

    PhaseBio Pharmaceuticals's latest funding round is IPO.

  • How much did PhaseBio Pharmaceuticals raise?

    PhaseBio Pharmaceuticals raised a total of $144.94M.

  • Who are the investors of PhaseBio Pharmaceuticals?

    Investors of PhaseBio Pharmaceuticals include Johnson & Johnson Innovation, Pisgah Fund, Fletcher Spaght Ventures, New Enterprise Associates, AstraZeneca and 10 more.

  • Who are PhaseBio Pharmaceuticals's competitors?

    Competitors of PhaseBio Pharmaceuticals include Catalyst Biosciences, Aerie, LungLife AI, Bird Rock Bio, Aphios and 14 more.

Compare PhaseBio Pharmaceuticals to Competitors

Oligomerix Logo

Oligomerix is a clinical-stage biotechnology company. It focuses on developing disease-modifying therapeutics for neurodegenerative diseases characterized by the aberrant tau protein, ranging from tauopathies such as progressive supranuclear palsy and frontotemporal dementia to Alzheimer’s disease. The firm serves clients in the healthcare sector. Oligomerix was founded in 2006 and is based in West Harrison, New York.

Aphios Logo

Biopharmaceutical company developing enabling technology platforms and enhanced natural therapeutics for certain infectious diseases, cancers and CNS disorders. Ehanced therapeutics include small molecules from medicinal plants and marine organisms, and improved drug delivery formulations of protein macromolecules and hydrophobic anticancer drugs.


TargAnox offers therapeutics to treat diseases resulting from oxidative stress-induced protein aging

Bolder BioTechnology

Bolder BioTechnology, Inc. uses advanced protein engineering technologies to create human protein pharmaceuticals with enhanced therapeutic properties. Most protein pharmaceuticals are rapidly eliminated by the body, which limits their effectiveness and requires that they be administered by frequent, often daily, injection. The company's products are designed to last longer in the body, which aims to allow them to be administered less frequently, e.g., once per week to once per month, and maximizes their therapeutic benefits to patients. Company scientists combine protein structure/function information with targeted protein modification technologies to rationally design long-acting protein pharmaceuticals that, in many cases, are 10-100-fold more potent than competing products prepared using non-targeted protein modification technologies. Bolder BioTechnology has a robust pipeline of products in preclinical development, including products for the treatment of hematological and endocrine disorders, cancer and infectious disease. The company intend to commercialize these products independently and through strategic alliances with corporate partners.

Hawaii Biotech

Hawaii Biotech (HBI) is a privately held biotechnology company focused on the research and development of vaccines for established and emerging infectious diseases. The company has developed expertise in the production of recombinant proteins applicable to the development of safe and effective vaccines. Lead vaccine candidates in clinical development target the West Nile virus and Dengue virus. Additional recombinant protein subunits vaccine candidates produced from this protein production platform are currently under development.


AM-Pharma is a biopharmaceutical company that focuses on the development of recombinant Alkaline Phosphatase for clinical use.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.